Gastroenterology

medical specialties

The week's innovation in gastroenterology, published every Sunday for the week before: new technology, AI tools, devices, FDA decisions on new technology and new ways of delivering care, every item linked to its sources.

Elebsiran-tobevibart meets phase 3 hepatitis delta goal; efinopegdutide resolves MASH in phase 2b; dabigatran recanalizes portal vein thrombosis

A flexible endoscope with its control head and two round angulation wheels, its long insertion tube coiling in a loose loop on a table.

Vir Biotechnology said 44% of patients given elebsiran and tobevibart reached undetectable hepatitis delta virus RNA with ALT normalization at week 48 in the phase 3 ECLIPSE 1 trial.

Efinopegdutide resolved MASH in up to 63% of patients versus 13% with placebo in a phase 2b trial, and dabigatran recanalized portal vein thrombosis in 64.3% versus 21.4% with placebo in cirrhosis.

Latest news

Tagged gastroenterology, from the daily briefing

  1. Interim results published from a randomized trial of surveillance colonoscopy intervals after polypectomy
  2. IDSA issues 2026 guideline on preventing invasive aspergillosis in adult solid organ transplant recipients
  3. Enterocolitis hit 3% of 1,308 cilta-cel recipients with myeloma, at a median 75 days after infusion

See all the latest news

Earlier weeks

The weekly podcast

Each Sunday's gastroenterology innovation roundup as a short audio briefing, read by AI voices. Play any episode here, or follow the show in any podcast app.

In any podcast app, add the feed: https://feeds.transistor.fm/physician-in-the-loop-gastroenterology